BDR Pharma launches generic version of Lenvatinib drug for cancer treatment
BDR Pharmaceuticals on Wednesday said it has launched the generic version
ofLenvatinib drug for the treatmentof various types of cancers in India.
The generic version of the drug has been
launched under the brand name 'Bdfoie' in the country.
Thecapsules are usedfor the treatment of differentiated
thyroid cancer, advanced liver cancer and advanced kidney cancer,BDR Pharma
said in a statement.
The results of clinical trials showed
encouraging results with safety and efficacy on patients with aggressive
tumours, it added.
The drug is priced at Rs 1,620 (4 mg) and Rs
2,970 (10 mg) for a pack of 10 capsules,the statement said.
"By launching cost-effective therapy
options we want to mitigate the challenges faced by Indian patients in seeking
access to treatment and finding a timely cure for life threatening
diseases,"BDR Pharmaceuticals CMDDharmesh Shah said. Read More
Comments
Post a Comment